PET Detection of CCR2 in Human Atherosclerosis
PET 检测人动脉粥样硬化中的 CCR2
基本信息
- 批准号:9905207
- 负责人:
- 金额:$ 76.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-02-01 至 2025-01-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAmericanAnti-Inflammatory AgentsAreaArterial Fatty StreakAtherosclerosisAutoradiographyBindingBiologicalBiological AssayBone MarrowCCL2 geneCCR1 geneCardiovascular DiseasesCarotid ArteriesCell LineCellsCharacteristicsCopperDataDetectionDiabetes MellitusDiagnosisDiseaseDisease ProgressionEndarterectomyEvaluationFluorescence-Activated Cell SortingFoundationsFutureGene ExpressionHematopoiesisHemorrhageHost DefenseHumanImageImage AnalysisImaging DeviceImmuneImmunohistochemistryInflammationInflammatoryLesionMeasurementMediatingModelingModernizationMolecularMolecular ProfilingMonitorMulticenter StudiesOutcome StudyPathway interactionsPatientsPeptidesPerformancePeripheralPeripheral arterial diseasePhenotypePlayPopulations at RiskPositron-Emission TomographyProcessRadiolabeledReproducibilityResearchReverse Transcriptase Polymerase Chain ReactionRiskRisk FactorsRoleSamplingSeminalSignal TransductionSiteSmokingSpleenThrombosisTissuesVolunteer Groupbasecalcificationcardiovascular disorder riskchemokinechemokine receptorcomorbiditycytokinedesignextracellularfemoral arteryhigh risk populationhuman subjectimaging approachimaging studyin vivo imaginginterestmacrophagemonocytemonocyte chemoattractant protein 1 receptormortalitynovel therapeuticsoptimal treatmentsoutcome forecastpatient populationpre-clinicalradiotracerreceptorreceptor expressionrecruittargeted imagingtraffickingtranscriptomicstreatment responsevolunteer
项目摘要
A central modern tenet of atherosclerosis is that inflammation is a key driver of the process, and likely provides
at least a partial explanation for the excess CVD risk observed even after optimal treatment of traditional risk
factors. There is a critical unmet need for imaging tools that accurately risk stratify atherosclerotic patients based
on their inflammatory phenotype and identify those where a given therapy is indicated and then monitor its effect.
The monocyte chemoattractant protein-1 / C-C chemokine receptor type 2 (MCP-1/CCR2) axis is of particular
interest due to its central role in recruitment of pro-inflammatory monocytes which through their conversion of
pro-inflammatory macrophages are crucial for early atherosclerotic lesion formation and its progression. We
have developed a copper-64 radiolabeled extracellular loop 1 inverso (ECL1i) peptide PET radiotracer that
targets CCR2 ([64Cu]DOTA-ECL1i). We have shown this radiotracer provides sensitive and specific detection of
CCR2 receptor expression in a human monocytic cell line and ex-vivo human peripheral arterial atherosclerotic
plaque and tracks disease progression and treatment response in pre-clinical atherosclerotic models. Moreover,
we have initial human subject PET data to suggest [64Cu]DOTA-ECL1i noninvasively detects atherosclerotic
lesions.
Our objective is to perform the initial evaluation of the imaging performance of [64Cu]DOTA-ECL1i in humans
with peripheral carotid and femoral arterial atherosclerosis and obtain key biological information that is
foundational for the design of future studies to assess its capability for diagnosis, prognosis assignment and
evaluation of new therapies. To achieve this objective we will address, in parallel, the following Aims:
Aim 1. Evaluate the performance of [64Cu]DOTA-ECL1i PET/MR to detect CCR2+ monocytes and
macrophages in atherosclerotic plaques from patients undergoing carotid or femoral endarterectomy
(CEA and FEA): In Aim 1A we will evaluate the imaging characteristics of [64Cu]DOTA-ECL1i in normal
volunteers (Group 1) and in patients undergoing CEA (Group 2) or FEA (Group 3). Imaging performance will be
determined by correlation with standard MR readouts of plaque presence, size and stage and with ex-vivo tissue
measurements of CCR2 content/expression and inflammation determined by autoradiography and molecular
profiling assays. As an exploratory Aim we will assess the relationship between hematopoiesis and
atherosclerotic plaque progression. In Aim 1B we will determine the reproducibility of this approach in patients
with carotid and femoral artery atherosclerotic occlusive disease managed non-operatively.
Aim 2. Determine in ex-vivo human atherosclerotic CEA and FEA plaque samples the relationship
between [64Cu]DOTA-ECL1i binding, CCR2+ cellular expression, immune cell composition, cytokine
expression and plaque complexity. Atheromas are often heterogeneous with areas of variable intraplaque
calcification, hemorrhage, and inflammation. We will define lesion types with variable [64Cu]DOTA-ECL1i signal
and characterize their cellular and molecular composition using autoradiography, multiplex
immunohistochemistry and spatial transcriptomics. As an exploratory analysis, we will correlate findings from
Aims 1A and 2A with known co-morbidities and risk factors for peripheral arterial atherosclerosis to determine
if there are specific patient populations that are more likely to have higher or lower CCR2 plaque content.
Successful completion of the proposed research will permit delineation of the importance of CCR2 expression
in human atherosclerosis, particularly involving sites that are relatively understudied such as peripheral arterial
disease. These results will lay the foundation for larger seminal multi-center studies to assess our imaging
approach to noninvasively detect CCR2 expressing cells in human atherosclerosis.
动脉粥样硬化的一个中心现代原则是炎症是该过程的关键驱动因素,并可能提供
至少部分解释了即使在传统风险的最佳治疗后观察到的过度CVD风险
因素对于基于动脉粥样硬化患者的准确风险分层的成像工具存在关键的未满足的需求。
对他们的炎症表型,并确定那些给定的治疗是指,然后监测其效果。
单核细胞趋化蛋白-1/ C-C趋化因子受体2(MCP-1/CCR 2)轴是一个特殊的细胞周期。
由于其在促炎性单核细胞的募集中的中心作用,
促炎性巨噬细胞对于早期动脉粥样硬化损伤形成及其进展是至关重要的。我们
已经开发了一种铜-64放射性标记的细胞外环1反向(ECL 1 i)肽PET放射性示踪剂,
靶向CCR 2([64 Cu] DOTA-ECL 1 i)。我们已经表明,这种放射性示踪剂提供了灵敏和特异性的检测,
CCR 2受体在人单核细胞系和离体人外周动脉粥样硬化中的表达
在临床前动脉粥样硬化模型中监测斑块并跟踪疾病进展和治疗反应。此外,委员会认为,
我们有初步的人类受试者PET数据表明[64 Cu] DOTA-ECL 1 i非侵入性检测动脉粥样硬化
病变
我们的目标是对[64 Cu] DOTA-ECL 1 i在人体中的成像性能进行初步评价
外周颈动脉和股动脉粥样硬化,并获得关键的生物信息,
未来研究设计的基础,以评估其诊断能力,预后分配,
评估新疗法。为实现这一目标,我们将同时致力于以下目标:
目标1.评价[64 Cu] DOTA-ECL 1 i PET/MR检测CCR 2+单核细胞的性能,
接受颈动脉或股动脉内膜切除术患者动脉粥样硬化斑块中的巨噬细胞
(CEA和FEA):在目标1A中,我们将评价正常人中[64 Cu] DOTA-ECL 1 i的成像特征。
志愿者(第1组)和接受CEA(第2组)或FEA(第3组)的患者。成像性能将是
通过与斑块存在、大小和阶段的标准MR读数以及与离体组织的相关性来确定
通过放射自显影和分子生物学方法测定CCR 2含量/表达和炎症
谱分析测定。作为探索性目的,我们将评估造血与
动脉粥样硬化斑块进展。在目标1B中,我们将确定这种方法在患者中的重现性
非手术治疗颈动脉和股动脉粥样硬化闭塞性疾病。
目标二。测定离体人动脉粥样硬化斑块标本CEA与FEA的关系
[64 Cu] DOTA-ECL 1 i结合、CCR 2+细胞表达、免疫细胞组成、细胞因子
表达和斑块复杂性。动脉粥样硬化通常是异质性的,斑块内的区域不同
钙化出血和炎症我们将使用可变[64 Cu] DOTA-ECL 1 i信号定义病变类型
并使用放射自显影、多重
免疫组织化学和空间转录组学。作为一项探索性分析,我们将从
目的1A和2A与已知的合并症和外周动脉粥样硬化的风险因素,以确定
如果有特定的患者群体更可能具有更高或更低的CCR 2斑块含量。
成功完成拟议的研究将允许描绘CCR 2表达的重要性,
在人类动脉粥样硬化中,特别是涉及相对研究不足的部位,如外周动脉,
疾病这些结果将为更大的开创性多中心研究奠定基础,以评估我们的成像
非侵入性检测人动脉粥样硬化中CCR 2表达细胞的方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Robert J. Gropler其他文献
Vulnerable or High-Risk Plaque: A emJACC: Cardiovascular Imaging/em Position Statement
易损或高危斑块:JACC:心血管影像学立场声明
- DOI:
10.1016/j.jcmg.2024.12.004 - 发表时间:
2025-06-01 - 期刊:
- 影响因子:15.200
- 作者:
Rocco Vergallo;Seung-Jung Park;Gregg W. Stone;David Erlinge;Italo Porto;Ron Waksman;Gary S. Mintz;Fabrizio D’Ascenzo;Sara Seitun;Luca Saba;Rozemarijn Vliegenthart;Fernando Alfonso;Armin Arbab-Zadeh;Peter Libby;Marcelo F. Di Carli;James E. Muller;Gerald Maurer;Robert J. Gropler;Y.S. Chandrashekhar;Eugene Braunwald;Ik-Kyung Jang - 通讯作者:
Ik-Kyung Jang
Recovery of contractile function in viable but dysfunctional myocardium is dependent upon maintenance of oxidative metabolism
- DOI:
10.1016/0735-1097(90)92527-9 - 发表时间:
1990-02-01 - 期刊:
- 影响因子:
- 作者:
Robert J. Gropler;Barry A. Siegel;Julio E. Perez;Steven R. Bergmann;Robert G. Kopitsky;Burton E. Sobel;Edward M. Geltman - 通讯作者:
Edward M. Geltman
Myocardial Perfusion PET for the Detection and Reporting of Coronary Microvascular Dysfunction: A emJACC: Cardiovascular Imaging/em Expert Panel Statement
心肌灌注正电子发射断层扫描在冠状动脉微血管功能障碍检测和报告中的应用:JACC:心血管影像学专家小组声明
- DOI:
10.1016/j.jcmg.2022.12.015 - 发表时间:
2023-04-01 - 期刊:
- 影响因子:15.200
- 作者:
Thomas H. Schindler;William F. Fearon;Matthieu Pelletier-Galarneau;Giuseppe Ambrosio;Udo Sechtem;Terrence D. Ruddy;Krishna K. Patel;Deepak L. Bhatt;Timothy M. Bateman;Henry Gewirtz;Jamshid Shirani;Juhani Knuuti;Robert J. Gropler;Panithaya Chareonthaitawee;Riemer H.J.A. Slart;Stephan Windecker;Philipp A. Kaufmann;Maria R. Abraham;Viviany R. Taqueti;Thomas J. Ford;Vasken Dilsizian - 通讯作者:
Vasken Dilsizian
Journey to find the ideal PET flow tracer for clinical use: Are we there yet?
- DOI:
10.1016/j.nuclcard.2007.09.019 - 发表时间:
2007-11-01 - 期刊:
- 影响因子:2.700
- 作者:
David K. Glover;Robert J. Gropler - 通讯作者:
Robert J. Gropler
Ninth nuclear cardiology invitational conference, Annapolis, Maryland, 2008
- DOI:
10.1007/bf03007373 - 发表时间:
2008-11-01 - 期刊:
- 影响因子:2.700
- 作者:
Ernest V. Garcia;Robert J. Gropler - 通讯作者:
Robert J. Gropler
Robert J. Gropler的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Robert J. Gropler', 18)}}的其他基金
PET Imaging of MMP Activation in AAA: First in-Human Evaluation
AAA 中 MMP 激活的 PET 成像:首次人体评估
- 批准号:
10226098 - 财政年份:2020
- 资助金额:
$ 76.5万 - 项目类别:
CCR2 Targeted Molecular Imaging and Treatment of Abdominal Aortic Aneurysms
CCR2 靶向分子成像和腹主动脉瘤治疗
- 批准号:
10487405 - 财政年份:2020
- 资助金额:
$ 76.5万 - 项目类别:
PET Detection of CCR2 in Human Atherosclerosis
PET 检测人动脉粥样硬化中的 CCR2
- 批准号:
10565938 - 财政年份:2020
- 资助金额:
$ 76.5万 - 项目类别:
CCR2 Targeted Molecular Imaging and Treatment of Abdominal Aortic Aneurysms
CCR2 靶向分子成像和腹主动脉瘤治疗
- 批准号:
10219893 - 财政年份:2020
- 资助金额:
$ 76.5万 - 项目类别:
PET Detection of CCR2 in Human Atherosclerosis
PET 检测人动脉粥样硬化中的 CCR2
- 批准号:
10361392 - 财政年份:2020
- 资助金额:
$ 76.5万 - 项目类别:
PET Imaging of MMP Activation in AAA: First in-Human Evaluation
AAA 中 MMP 激活的 PET 成像:首次人体评估
- 批准号:
10617801 - 财政年份:2020
- 资助金额:
$ 76.5万 - 项目类别:
PET Detection of CCR2 in Human Atherosclerosis
PET 检测人动脉粥样硬化中的 CCR2
- 批准号:
10091521 - 财政年份:2020
- 资助金额:
$ 76.5万 - 项目类别:
PET Imaging of MMP Activation in AAA: First in-Human Evaluation
AAA 中 MMP 激活的 PET 成像:首次人体评估
- 批准号:
10371169 - 财政年份:2020
- 资助金额:
$ 76.5万 - 项目类别:
CCR2 Targeted Molecular Imaging and Treatment of Abdominal Aortic Aneurysms
CCR2 靶向分子成像和腹主动脉瘤治疗
- 批准号:
10673716 - 财政年份:2020
- 资助金额:
$ 76.5万 - 项目类别:
THE PET RADIOTRACER TRANSLATION AND RESOURCE CENTER (PET-RTRC)
PET 放射示踪剂翻译和资源中心 (PET-RTRC)
- 批准号:
10480874 - 财政年份:2018
- 资助金额:
$ 76.5万 - 项目类别:
相似海外基金
Collaborative Research: REU Site: Earth and Planetary Science and Astrophysics REU at the American Museum of Natural History in Collaboration with the City University of New York
合作研究:REU 地点:地球与行星科学和天体物理学 REU 与纽约市立大学合作,位于美国自然历史博物馆
- 批准号:
2348998 - 财政年份:2025
- 资助金额:
$ 76.5万 - 项目类别:
Standard Grant
Collaborative Research: REU Site: Earth and Planetary Science and Astrophysics REU at the American Museum of Natural History in Collaboration with the City University of New York
合作研究:REU 地点:地球与行星科学和天体物理学 REU 与纽约市立大学合作,位于美国自然历史博物馆
- 批准号:
2348999 - 财政年份:2025
- 资助金额:
$ 76.5万 - 项目类别:
Standard Grant
Understanding Latin American Challenges in the 21st Century (LAC-EU)
了解拉丁美洲在 21 世纪面临的挑战 (LAC-EU)
- 批准号:
EP/Y034694/1 - 财政年份:2024
- 资助金额:
$ 76.5万 - 项目类别:
Research Grant
Conference: North American High Order Methods Con (NAHOMCon)
会议:北美高阶方法大会 (NAHOMCon)
- 批准号:
2333724 - 财政年份:2024
- 资助金额:
$ 76.5万 - 项目类别:
Standard Grant
Collaborative Research: RUI: Continental-Scale Study of Jura-Cretaceous Basins and Melanges along the Backbone of the North American Cordillera-A Test of Mesozoic Subduction Models
合作研究:RUI:北美科迪勒拉山脊沿线汝拉-白垩纪盆地和混杂岩的大陆尺度研究——中生代俯冲模型的检验
- 批准号:
2346565 - 财政年份:2024
- 资助金额:
$ 76.5万 - 项目类别:
Standard Grant
REU Site: Research Experiences for American Leadership of Industry with Zero Emissions by 2050 (REALIZE-2050)
REU 网站:2050 年美国零排放工业领先地位的研究经验 (REALIZE-2050)
- 批准号:
2349580 - 财政年份:2024
- 资助金额:
$ 76.5万 - 项目类别:
Standard Grant
Collaborative Research: RUI: Continental-Scale Study of Jura-Cretaceous Basins and Melanges along the Backbone of the North American Cordillera-A Test of Mesozoic Subduction Models
合作研究:RUI:北美科迪勒拉山脊沿线汝拉-白垩纪盆地和混杂岩的大陆尺度研究——中生代俯冲模型的检验
- 批准号:
2346564 - 财政年份:2024
- 资助金额:
$ 76.5万 - 项目类别:
Standard Grant
Conference: Latin American School of Algebraic Geometry
会议:拉丁美洲代数几何学院
- 批准号:
2401164 - 财政年份:2024
- 资助金额:
$ 76.5万 - 项目类别:
Standard Grant
Collaborative Research: Ionospheric Density Response to American Solar Eclipses Using Coordinated Radio Observations with Modeling Support
合作研究:利用协调射电观测和建模支持对美国日食的电离层密度响应
- 批准号:
2412294 - 财政年份:2024
- 资助金额:
$ 76.5万 - 项目类别:
Standard Grant
Conference: Doctoral Consortium at Student Research Workshop at the Annual Conference of the North American Chapter of the Association for Computational Linguistics (NAACL)
会议:计算语言学协会 (NAACL) 北美分会年会学生研究研讨会上的博士联盟
- 批准号:
2415059 - 财政年份:2024
- 资助金额:
$ 76.5万 - 项目类别:
Standard Grant